Hyundai Bioscience Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 2,463.02 million compared to KRW 2,960.04 million a year ago. Net loss was KRW 2,591.9 million compared to KRW 321.9 million a year ago. Basic loss per share from continuing operations was KRW 71 compared to KRW 9 a year ago. Diluted loss per share from continuing operations was KRW 71 compared to KRW 9 a year ago. Basic loss per share was KRW 71 compared to KRW 9 a year ago.
For the nine months, sales was KRW 227.53 million compared to KRW 45 million a year ago. Net loss was KRW 6,537.93 million compared to KRW 1,682.46 million a year ago. Basic loss per share from continuing operations was KRW 180 compared to KRW 47 a year ago. Diluted loss per share from continuing operations was KRW 180 compared to KRW 47 a year ago. Basic loss per share was KRW 180 compared to KRW 47 a year ago.